Information only. Not medical advice, and not a recommendation to use any compound. We do not sell or supply any compound Speak to a doctor before any decision about your health Information only. Not medical advice, and not a recommendation to use any compound. We do not sell or supply any compound Speak to a doctor before any decision about your health Information only. Not medical advice, and not a recommendation to use any compound. We do not sell or supply any compound Speak to a doctor before any decision about your health
Genexis Health

Retatrutide

Also known as LY3437943 · triple agonist · developed by Eli Lilly

Phase 3 trials

Large randomised trials in humans are complete or under way, but the compound is not licensed. Efficacy and common adverse effects are reasonably well characterised; long-term safety may not be.

Investigational — not approved In clinical development. Not licensed by any major regulator, so it has not been judged safe or effective for any use.
Illustration only. Not a photograph of a product, and not an offer of supply — Genexis Health does not sell or supply Retatrutide.

What it is

An investigational agonist at three receptors — GIP, GLP-1 and glucagon. The glucagon component is what distinguishes it, and is intended to raise energy expenditure alongside the appetite suppression the other two provide.

How it is thought to work

Triple agonist. Glucagon receptor activation increases hepatic energy expenditure and lipolysis, which in principle adds a metabolic-rate effect to the intake reduction seen with GLP-1 and GIP agonism.

What the studies found

  • The largest weight reduction reported for a drug to date

    A phase 2 trial published in the New England Journal of Medicine in 2023 reported mean weight loss of approximately 24% at 48 weeks at the highest dose, in 338 participants. Weight had not clearly plateaued when the trial ended.

  • Phase 3 under way

    The TRIUMPH programme is running across obesity, type 2 diabetes, knee osteoarthritis and cardiovascular outcomes. Results are not yet available.

What the evidence does not show

  • No phase 3 results have been published. Phase 2 findings frequently shrink at phase 3, and roughly a third of drugs entering phase 3 still fail.
  • The phase 2 trial ran 48 weeks in 338 people. That is too small and too short to characterise uncommon adverse events.
  • A dose-dependent increase in heart rate was observed. Its long-term significance is unknown.
  • No approved dose exists, because no regulator has evaluated it.

Reported risks and adverse effects

  • Gastrointestinal effects were the most common adverse events and were dose-related.
  • Heart rate increased in a dose-dependent way in phase 2.
  • The full adverse event profile is genuinely unknown — that is what phase 3 is for.
  • Material sold outside clinical trials has no verified identity, purity or sterility, and no regulator is checking it.

This is a summary of what has been reported in the literature, not a complete safety profile. For anything concerning your own health, speak to a doctor.

Regulatory status

Not approved by any regulator anywhere in the world. It is an investigational product, legally available only through the clinical trials running it.

Where it acts

The sites below are where Retatrutide is understood to act, paired with what was actually measured there and in whom. A site on this diagram means a compound acts there — not that a benefit is established.

Drag to turn · tap an organ

123
Stylised illustration. Marker positions are indicative, not anatomically precise.
  1. GLP-1 and GIP receptor agonism reducing energy intake.

    What was measuredPhase 2 (n≈338): mean weight loss ≈24.2% at 48 weeks on the highest dose. Phase 3 is under way and has not reported.

  2. Increases glucose-dependent insulin secretion and suppresses glucagon.

    What was measuredPhase 2 glycaemic endpoints were favourable. No phase 3 outcome data exists yet.

  3. Glucagon receptor agonism is proposed to raise hepatic energy expenditure and lipolysis.

    What was measuredThis is the arm that distinguishes it from dual agonists. The size of its contribution in humans is not yet established.